Latest Articles

Publication Date
Expert opinion on best practice in programmed frozen embryo transfers: a Delphi consensus.

How can outcomes in programmed frozen embryo transfers (FET) be improved, and what are the key areas where more research is needed?

Published: June 10, 2026, midnight
Multiple recurrences of postmenopausal endometriosis associated with estrogen pellet therapy: clinical implications for hormone therapy and surgical management.

To challenge the perception that endometriosis uniformly regresses after menopause by presenting the case of repeated, pathology-confirmed symptomatic recurrences spanning two decades after menopause, and to emphasize key considerations for …

Published: June 9, 2026, midnight
Comparative post-marketing reporting signals of elagolix and myfembree in endometriosis: a FAERS pharmacovigilance study.

Elagolix and Myfembree are gonadotropin-releasing hormone (GnRH)-pathway therapies used for endometriosis, but their post-marketing safety reporting patterns remain incompletely characterized. Because spontaneous reporting databases are susceptible to reporting bias and …

Published: June 5, 2026, midnight
RE-1 silencing transcription factor is reduced in endometriosis and uterine deletion in mice alters progesterone responsiveness.

Endometriosis is a steroid-dependent gynecologic disease characterized by progesterone (P4) resistance, subfertility/infertility, and pelvic pain; however, the molecular mechanisms underlying impaired P4 responsiveness in endometriosis tissue are not fully understood. …

Published: June 3, 2026, midnight
Roles of Goserelin in Gynecological Disorders.

Goserelin is a gonadotropin-releasing hormone (GnRH) agonist with a long history of clinical application and well-established efficacy and safety profile. Its mechanism of action centers on sustained GnRH receptor desensitization, …

Published: May 27, 2026, midnight
MicroRNAs in endometriosis: bioinformatics resources, machine learning strategies, and multi-omics perspectives.

Endometriosis is a heterogeneous gynecological disorder characterized by chronic pain, infertility, and substantial impairment of quality of life. Increasing evidence indicates that microRNAs (miRNAs) are key regulators of endometriosis pathogenesis …

Published: May 25, 2026, midnight
Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions†.

Estrogen stimulates corticotropin-releasing hormone (CRH) expression in endometrial tissue, and CRH signaling contributes to inflammation and pain, suggesting a mechanistic role in endometriosis pathophysiology. We previously identified elevated CRH receptor-1 …

Published: May 22, 2026, midnight
Does endometrioma diameter impact serum anti-Müllerian hormone levels? A systematic review and meta-analysis.

Is endometrioma diameter associated with ovarian reserve, as reflected by serum anti-Müllerian hormone (AMH) levels, in women of reproductive age with no history of ovarian surgery?

Published: May 22, 2026, midnight
Is Recurrent Endometriosis a Reprogrammed Disease? Molecular Persistence Beyond Surgical Clearance.

Background: Endometriosis is traditionally conceptualized as a localized gynecological disorder characterized by the presence of ectopic endometrial tissue. However, high recurrence rates following apparently complete surgical excision challenge this lesion-based …

Published: May 21, 2026, midnight
Anti-Müllerian hormone decreased in women with superficial peritoneal endometriosis and associated with an elevated inflammatory profile.

Endometriosis is a common, inflammatory condition impacting 200 million women and those assigned female at birth, where 25-40% experience infertility. Ovarian endometriosis is known to decrease anti-Mullerian hormone (AMH) levels …

Published: May 19, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!